Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Metabolism and disposition of MM-433593, a selective FAAH-1 inhibitor, in monkeys.

Banijamali AR, Wakefield JD, Mermerian AH, Busby RW.

Pharmacol Res Perspect. 2014 Oct;2(5):e00059. doi: 10.1002/prp2.59. Epub 2014 Jul 2.

2.

Clarification of linaclotide pharmacology presented in a recent clinical study of plecanatide.

Busby RW, Ortiz S.

Dig Dis Sci. 2014 May;59(5):1066-7. doi: 10.1007/s10620-013-2953-x. Epub 2014 Mar 21. No abstract available.

3.

Linaclotide pharmacodynamics.

Busby RW, Zhang G.

P T. 2013 Jul;38(7):397. No abstract available.

4.

Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.

Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, Solinga RM, Tobin JV, Wakefield JD, Kurtz CB, Currie MG.

J Pharmacol Exp Ther. 2013 Jan;344(1):196-206. doi: 10.1124/jpet.112.199430. Epub 2012 Oct 22.

PMID:
23090647
5.

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.

Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Mahajan-Miklos S, Pierce CM, Solinga RM, Sun LJ, Tobin JV, Kurtz CB, Currie MG.

Eur J Pharmacol. 2010 Dec 15;649(1-3):328-35. doi: 10.1016/j.ejphar.2010.09.019. Epub 2010 Sep 20.

PMID:
20863829
6.

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.

Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Pierce CM, Solinga RM, Tobin JV, Mahajan-Miklos S, Cohen MB, Kurtz CB, Currie MG.

Life Sci. 2010 May 8;86(19-20):760-5. doi: 10.1016/j.lfs.2010.03.015. Epub 2010 Mar 20.

PMID:
20307554
7.

Escherichia coli LipA is a lipoyl synthase: in vitro biosynthesis of lipoylated pyruvate dehydrogenase complex from octanoyl-acyl carrier protein.

Miller JR, Busby RW, Jordan SW, Cheek J, Henshaw TF, Ashley GW, Broderick JB, Cronan JE Jr, Marletta MA.

Biochemistry. 2000 Dec 12;39(49):15166-78.

PMID:
11106496
9.
12.

A strategy for identifying novel, mechanistically unique inhibitors of topoisomerase I.

Hecht SM, Berry DE, MacKenzie LJ, Busby RW, Nasuti CA.

J Nat Prod. 1992 Apr;55(4):401-13.

PMID:
1324981
13.

Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site.

Hertzberg RP, Busby RW, Caranfa MJ, Holden KG, Johnson RK, Hecht SM, Kingsbury WD.

J Biol Chem. 1990 Nov 5;265(31):19287-95.

Supplemental Content

Loading ...
Support Center